Fagron NV (FAGR) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.167x

Based on the latest financial reports, Fagron NV (FAGR) has a cash flow conversion efficiency ratio of 0.167x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€93.07 Million ≈ $108.81 Million USD) by net assets (€556.26 Million ≈ $650.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Fagron NV - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Fagron NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Fagron NV for a breakdown of total debt and financial obligations.

Fagron NV Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Fagron NV ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
China Security & Fire Co Ltd Class A
SHG:600654
-0.009x
Collective Mining Ltd
TO:CNL
-0.091x
Celltrion Pharm Inc
KQ:068760
0.055x
Mister Car Wash, Inc. Common Stock
NYSE:MCW
0.083x
Jiangsu Jiangyin Rural Commercial Bank Co Ltd
SHE:002807
0.543x
Airport City Ltd
TA:ARPT
0.019x
Hotel Shilla
KO:008770
-0.137x
KTK Group Co Ltd
SHG:603680
0.004x

Annual Cash Flow Conversion Efficiency for Fagron NV (2004–2025)

The table below shows the annual cash flow conversion efficiency of Fagron NV from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Fagron NV.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €556.26 Million
≈ $650.32 Million
€128.28 Million
≈ $149.97 Million
0.231x +6.05%
2024-12-31 €505.36 Million
≈ $590.82 Million
€109.89 Million
≈ $128.48 Million
0.217x -5.30%
2023-12-31 €467.63 Million
≈ $546.70 Million
€107.38 Million
≈ $125.54 Million
0.230x -14.28%
2022-12-31 €408.63 Million
≈ $477.73 Million
€109.46 Million
≈ $127.97 Million
0.268x +11.17%
2021-12-31 €325.47 Million
≈ $380.50 Million
€78.42 Million
≈ $91.68 Million
0.241x -33.17%
2020-12-31 €257.82 Million
≈ $301.42 Million
€92.95 Million
≈ $108.67 Million
0.361x +15.13%
2019-12-31 €246.44 Million
≈ $288.12 Million
€77.17 Million
≈ $90.23 Million
0.313x -10.38%
2018-12-31 €209.72 Million
≈ $245.18 Million
€73.28 Million
≈ $85.67 Million
0.349x -23.32%
2017-12-31 €184.88 Million
≈ $216.15 Million
€84.25 Million
≈ $98.49 Million
0.456x +3.20%
2016-12-31 €152.87 Million
≈ $178.73 Million
€67.50 Million
≈ $78.92 Million
0.442x +139.01%
2015-12-31 €-64.77 Million
≈ $-75.73 Million
€73.31 Million
≈ $85.71 Million
-1.132x -274.67%
2014-12-31 €156.94 Million
≈ $183.48 Million
€101.70 Million
≈ $118.89 Million
0.648x +59.40%
2013-12-31 €155.17 Million
≈ $181.41 Million
€63.08 Million
≈ $73.74 Million
0.407x +47.25%
2012-12-31 €245.38 Million
≈ $286.88 Million
€67.74 Million
≈ $79.20 Million
0.276x -15.64%
2011-12-31 €220.45 Million
≈ $257.73 Million
€72.15 Million
≈ $84.35 Million
0.327x +61.69%
2010-12-31 €208.12 Million
≈ $243.32 Million
€42.13 Million
≈ $49.25 Million
0.202x +0.63%
2009-12-31 €196.35 Million
≈ $229.56 Million
€39.50 Million
≈ $46.17 Million
0.201x +34.53%
2008-12-31 €185.53 Million
≈ $216.90 Million
€27.74 Million
≈ $32.43 Million
0.150x -1.67%
2007-12-31 €178.22 Million
≈ $208.36 Million
€27.10 Million
≈ $31.68 Million
0.152x -17.89%
2006-12-31 €94.88 Million
≈ $110.93 Million
€17.57 Million
≈ $20.54 Million
0.185x -55.57%
2005-12-31 €82.87 Million
≈ $96.88 Million
€34.54 Million
≈ $40.38 Million
0.417x +372.91%
2004-12-31 €102.54 Million
≈ $119.88 Million
€9.04 Million
≈ $10.57 Million
0.088x --

About Fagron NV

BR:FAGR Belgium Drug Manufacturers - Specialty & Generic
Market Cap
$2.06 Billion
€1.76 Billion EUR
Market Cap Rank
#6987 Global
#36 in Belgium
Share Price
€24.00
Change (1 day)
+0.00%
52-Week Range
€19.58 - €24.40
All Time High
€24.40
About

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Com… Read more